Although the buyout of Therakos (West Chester, Pa.) for about $1.3 billion is the second drug-device acquisition by Mallinckrodt (Dublin) this year, it s because of the synergies between the two firms involved in the deals rather than a preference for such technology per se, and Mallinckrodt wanted to be very clear that we are focused on specialty-branded drug products primarily, CEO Mark Trudeau told investors during a conference call. Read More
